{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:01:38Z","timestamp":1790186498532,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.oret.2024.05.021","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T21:08:43Z","timestamp":1725052123000},"page":"144-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"9","author":[{"given":"Peter A.","family":"Campochiaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-0668","authenticated-orcid":false,"given":"David","family":"Eichenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Lloyd","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Le Pogam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Cavichini Cordeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-5652","authenticated-orcid":false,"given":"Shamika","family":"Gune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mel","family":"Rabena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Callaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2024.05.021_bib1","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"3","author":"Solomon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.oret.2024.05.021_bib2","article-title":"Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","volume":"5","author":"Li","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.oret.2024.05.021_bib3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12886-020-01554-2","article-title":"Anti-vascular endothelial growth factor in neovascular age-related macular degeneration \u2013 a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems","volume":"20","author":"Finger","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2024.05.021_bib4","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration Preferred Practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.05.021_bib5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","article-title":"Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2024.05.021_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2024.05.021_bib7","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2024.05.021_bib8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","article-title":"SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States","volume":"4","author":"Khanani","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2024.05.021_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129361","article-title":"Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration","volume":"10","author":"Gohil","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2024.05.021_bib10","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","article-title":"Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study","volume":"160","author":"Prenner","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2024.05.021_bib11","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/OPTH.S92548","article-title":"Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey","volume":"9","author":"Varano","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2024.05.021_bib13","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.oret.2022.04.006","article-title":"Prevalence and progression of macular atrophy in eyes with neovascular age-related macular degeneration in the phase 2 Ladder trial of the Port Delivery System with ranibizumab","volume":"6","author":"Jaffe","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2024.05.021_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jconrel.2022.03.005","article-title":"In-vitro characterization of ranibizumab release from the Port Delivery System","volume":"345","author":"Yohe","year":"2022","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.oret.2024.05.021_bib15","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.05.021_bib16","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.oret.2020.11.004","article-title":"End-of-study results for the Ladder phase 2 trial of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration","volume":"5","author":"Khanani","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2024.05.021_bib17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.05.021_bib18","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1080\/10717544.2022.2069301","article-title":"The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery","volume":"29","author":"Ranade","year":"2022","journal-title":"Drug Deliv"},{"key":"10.1016\/j.oret.2024.05.021_bib19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ophtha.2023.02.024","article-title":"Archway phase 3 trial of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration 2-year results","volume":"130","author":"Regillo","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.05.021_bib26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3928\/23258160-20220408-01","article-title":"Implant insertion procedure of the Port Delivery System with ranibizumab: overview and clinical pearls","volume":"53","author":"Pieramici","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2024.05.021_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3928\/23258160-20220412-01","article-title":"Refill-exchange procedure of the Port Delivery System with ranibizumab: overview and clinical trial experience","volume":"53","author":"Khanani","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2024.05.021_bib28","article-title":"Endophthalmitis in eyes treated with the Port Delivery System with ranibizumab: summary of cases during clinical trial development","author":"Eichenbaum","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2024.05.021_bib29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3928\/23258160-20220415-03","article-title":"Conjunctiva and Tenon\u2019s capsule handling in the Port Delivery System with ranibizumab implant insertion procedure: surgical pearls","volume":"53","author":"Graff","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2024.05.021_bib30","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.oret.2022.05.011","article-title":"Management of key ocular adverse events in patients implanted with the Port Delivery System with ranibizumab","volume":"6","author":"Awh","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2024.05.021_bib32","first-page":"3121","article-title":"Archway phase 3 trial of the Port Delivery System with ranibizumab (PDS) for neovascular AMD: end-of-study results","volume":"63","author":"Mittra","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2024.05.021_bib33","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.oret.2022.03.021","article-title":"Longer-term anti-VEGF therapy outcomes in neovascular age-related macular degeneration, diabetic macular edema, and vein occlusion-related macular edema: clinical outcomes in 130 247 eyes","volume":"6","author":"Ciulla","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2024.05.021_bib34","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.05.021_bib35","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","article-title":"Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study","volume":"100","author":"Holz","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2024.05.021_bib36","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jamaophthalmol.2022.1091","article-title":"Patient preference and\u00a0treatment satisfaction with a Port Delivery System for\u00a0ranibizumab vs intravitreal injections in patients with\u00a0neovascular age-related macular degeneration: a randomized clinical trial","volume":"140","author":"Chang","year":"2022","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653024004007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653024004007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T09:00:01Z","timestamp":1738573201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653024004007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2468653024004007"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2024.05.021","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2024.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}